-
摘要: 肥厚型心肌病患者左心室流出道梗阻会增加不良结局的风险，疾病进展可能会出现严重的运动受限、心律失常和过早死亡。Aficamte是一种新型心脏肌球蛋白抑制剂，aficamten可抑制心脏肌节的过度收缩，改善肥厚型心肌病患者的心室肥厚，减轻左室流出道梗阻，进而改善心脏功能。本文主要阐述心脏肌球蛋白抑制剂aficamten在肥厚型心肌病防治方面的最新研究进展，为肥厚型心肌病的治疗提供新思路。Abstract: The presence of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy increases the risk of adverse outcomes. Disease progression may result in severe exercise limitation, cardiac arrhythmias, and premature death. Aficamten(CK-274) is a cardiac myosin inhibitor. Aficamten inhibits excessive contraction of cardiac muscle segments, improves ventricular hypertrophy in patients with hypertrophic cardiomyopathy, reduces left ventricular outflow tract obstruction, and thus improves cardiac function. The latest research progress of cardiac myosin inhibitor aficamten in the prevention and treatment of hypertrophic cardiomyopathy is described in the paper, which provides new ideas for the treatment of hypertrophic cardiomyopathy.
-
Key words:
- aficamten /
- CK-274 /
- myosin inhibitors /
- hypertrophic cardiomyopathy
-
-
[1] Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy[J]. Circ Res, 2017, 121(7): 749-770. doi: 10.1161/CIRCRESAHA.117.311059
[2] Sherrid MV. Drug therapy for hypertrophic cardiomypathy: physiology and practice[J]. Curr Cardiol Rev, 2016, 12(1): 52-65. doi: 10.2174/1573403X1201160126125403
[3] Makavos G, Kairis C, Tselegkidi ME, et al. Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment[J]. Heart Fail Rev, 2019, 24(4): 439-459. doi: 10.1007/s10741-019-09775-4
[4] Muresan ID, Agoston-Coldea L. Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging[J]. Heart Fail Rev, 2021, 26(5): 1023-1036. doi: 10.1007/s10741-020-09931-1
[5] Medical Masterclass contributors, Firth J. Cardiology: hypertrophic cardiomyopathy[J]. Clin Med(Lond), 2019, 19(1): 61-63.
[6] Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in(Young)Adults[J]. Circulation, 1995, 92(4): 785-789. doi: 10.1161/01.CIR.92.4.785
[7] Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779. doi: 10.1093/eurheartj/ehu284
[8] 吴明星, 黄泽旭, 慕家盛, 等. 肥厚型心肌病节段性心肌纤维化与微循环障碍之间的关系研究[J]. 临床心血管病杂志, 2021, 37(9): 840-846. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2021.09.012
[9] Maron MS, Rowin EJ, Olivotto I, et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol, 2016, 67(12): 1399-1409. doi: 10.1016/j.jacc.2016.01.023
[10] Malik FI, Robertson LA, Armas DR, et al. A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants[J]. JACC Basic Transl Sci, 2022, 7(8): 763-775. doi: 10.1016/j.jacbts.2022.04.008
[11] Krendel M, Mooseker MS. Myosins: tails(and heads)of functional diversity[J]. Physiology(Bethesda), 2005, 20: 239-251.
[12] Schmid M, Toepfer CN. Cardiac myosin super relaxation(SRX): a perspective on fundamental biology, human disease and therapeutics[J]. Biol Open, 2021, 10(2): bio057646. doi: 10.1242/bio.057646
[13] Marcucci L, Washio T, Yanagida T. Proposed mechanism for the length dependence of the force developed in maximally activated muscles[J]. Sci Rep, 2019, 9(1): 1317. doi: 10.1038/s41598-018-36706-4
[14] Zampieri M, Berteotti M, Ferrantini C, et al. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives[J]. Curr Heart Fail Rep, 2021, 18(4): 169-179. doi: 10.1007/s11897-021-00523-0
[15] Ferrantini C, Belus A, Piroddi N, et al. Mechanical and energetic consequences of HCM-causing mutations[J]. J Cardiovasc Transl Res, 2009, 2(4): 441-451. doi: 10.1007/s12265-009-9131-8
[16] Spudich JA. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations[J]. Pflugers Arch, 2019, 471(5): 701-717. doi: 10.1007/s00424-019-02259-2
[17] Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy[J]. Circulation, 2020, 141(10): 828-842. doi: 10.1161/CIRCULATIONAHA.119.042339
[18] Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396(10253): 759-769. doi: 10.1016/S0140-6736(20)31792-X
[19] Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten(CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy[J]. J Med Chem, 2021, 64(19): 14142-14152. doi: 10.1021/acs.jmedchem.1c01290
[20] Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy[J]. Circulation. 2020, 141(10): 828-842. doi: 10.1161/CIRCULATIONAHA.119.042339
[21] Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy[J]. Curr Cardiol Rep, 2021, 23(7): 79. doi: 10.1007/s11886-021-01508-0
[22] García-Giustiniani D, Arad M, Ortíz-Genga M, et al. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain[J]. Heart, 2015, 101(13): 1047-1053. doi: 10.1136/heartjnl-2014-307205
[23] Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A, 2018, 115(35): E8143-E8152.
[24] Kawas RF, Anderson RL, Ingle S, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle[J]. J Biol Chem, 2017, 292(40): 16571-16577. doi: 10.1074/jbc.M117.776815
[25] Tuohy CV, Kaul S, Song HK, et al. Hypertrophic cardiomyopathy: the future of treatment[J]. Eur J Heart Fail, 2020, 22(2): 228-240. doi: 10.1002/ejhf.1715
[26] 杨昭, 杨旭明, 杜来景. Mavacamten特异性治疗肥厚型心肌病的研究进展[J]. 临床心血管病杂志, 2022, 38(4): 267-271. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202204003.htm
[27] Hwee DT, Wu YS, Cremin P, et al. The cardiac myosin Inhibitor, CK-3773274, reduces contractility in the R403q mouse model of hypertrophic cardiomyopathy[EB/OL]. Circ Res, 2019, 125: A615.
[28] Argirò A, Zampieri M, Berteotti M, et al. Emerging Medical Treatment for Hypertrophic Cardiomyopathy[J]. J Clin Med, 2021, 10(5): 951. doi: 10.3390/jcm10050951
[29] Grillo MP, Erve J, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin[J]. Xenobiotica, 2019, 49(6): 718-733. doi: 10.1080/00498254.2018.1495856
[30] Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial[J]. Ann Intern Med, 2019, 170(11): 741-748. doi: 10.7326/M18-3016
[31] Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2023, 81(1): 34-45. doi: 10.1016/j.jacc.2022.10.020
[32] Owens AT, Masri A, Abraham TP, et al. Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM Cohort 3[J]. J Card Fail, 2023: S1071-9164(23)00261-0.
-
计量
- 文章访问数: 1838
- PDF下载数: 1220
- 施引文献: 0
下载: